These findings indicate that truncal alterations identified in primary PC can drive advanced mCRPC, even in the presence of additional strong oncogenic drivers (ie, RB1 loss and BRCA2 loss), and suggest that earlier detection and targeting of these truncal alterations may be effective at halting disease progression. This evidence concerns the gene RB1 and pachyonychia congenita.